Open AccessCOVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review
Author(s) -
Valentina Bonuomo,
Isacco Ferrarini,
Michele Dell’Eva,
Eugenio Sbisà,
Mauro Krampera,
Carlo Visco
Publication year - 2021
Publication title -
world journal of virology
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2220-3249
DOI - 10.5501/wjv.v10.i6.312
Subject(s) - medicine , lymphoma , disease , covid-19 , incidence (geometry) , coronavirus , cancer , immunology , intensive care medicine , infectious disease (medical specialty) , oncology , physics , optics
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection now has a global resonance and represents a major threat for several patient populations. Observations from initial case series suggested that cancer patients in general might have an unfavorable outcome following coronavirus disease 2019 (COVID-19), due to their underlying conditions and cytotoxic treatments. More recently, data regarding the incidence and clinical evolution of COVID-19 in lymphomas have been reported with the aim to identify those more frequently associated with severe complications and death. Patients with lymphoma appear particularly vulnerable to SARS-CoV-2 infection, only partly because of the detrimental effects of the anti-neoplastic regimens (chemotherapy, pathway inhibitors, monoclonal antibodies) on the immune system. Here, we systematically reviewed the current literature on COVID-19 in adult patients with lymphoma, with particular emphasis on disease course and prognostic factors. We also highlighted the potential differences in COVID-19 clinical picture according to lymphoma subtype, delivered treatment for the hematological disease and its relationship on how these patients have been managed thus far.